Phaseline

Companies › Disc Medicine

Disc Medicine: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 2 Phase 2, 2 Phase 1, 1 Phase 3; Hematology, Oncology, Immunology, Metabolic and endocrine; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bitopertin (DISC-1459)
Glycine transporter 1 inhibitor
SLC6A9Phase 3Erythropoietic Protoporphyria (EPP)–
DISC-0974–Phase 2Inflammatory Bowel Disease (IBD); Myelofibrosis; AnemiaMar 2027
DISC-3405–Phase 2Polycythemia Vera (PV); Sickle Cell DiseaseJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06910358Bitopertin (DISC-1459)Phase 3Erythropoietic Protoporphyria (EPP)Metabolic and endocrineSep 2026
NCT07368972DISC-0974Phase 2Inflammatory Bowel Disease (IBD)ImmunologyMar 2027
NCT05320198DISC-0974Phase 1Myelofibrosis; AnemiaHematologyMay 2027
NCT07187973DISC-3405Phase 1Sickle Cell DiseaseHematologyJun 2027
NCT06985147DISC-3405Phase 2Polycythemia Vera (PV)OncologyJul 2027

From the company's SEC filings

Cash and short-term investments of $683m on 2026-09-30; operating cash outflow about $197m a year; runway about 42 months at that burn, to Mar 2030; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Specialist investors

Held by 13 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

SLC6A9 (1)

Companies with the same targets

–

Companies built like this

Karyopharm Therapeutics Agios Pharmaceuticals Theravia Omeros Syntrix Biosystems

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.